Analyst Price Targets — AURX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 15, 2025 9:05 pm | Kyle Bauser | Roth Capital | $3.00 | $2.15 | TheFly | Nuo Therapeutics initiated with a Buy at Roth Capital |
Latest News for AURX
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary Total revenues of approximately $1.3 million…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AURX.
U.S. House Trading
No House trades found for AURX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.